Risperidone long-acting injection, a promising treatment for patients with bipolar disorder

References

• American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. American Journal of Psychiatry 1994; 151(Suppl.)1–36
   Google Scholar
• Baldessarini R. J., Tondo L., Viguera A. C. Discontinuing lithium maintenance treatment in bipolar disorders: Risks and implications. Bipolar Disorders 1999; 1: 17–24
   PubMedGoogle Scholar
• Bech P., Rafaelsen O. J., Kramp B., Bolwig T. G. The mania rating scale: Scale construction and inter-observer agreement. Neuropharmacology 1978; 17: 430–431
   PubMed Web of Science ®Google Scholar
• Berky M., Wolf C., Kovacs G. Carbamazepine versus lithium in bipolar affective disorders. European Archives of Psychiatry and Clinical Neuroscience 1998; 248: S119
   Google Scholar
• Chue P., Eerdekens M., Augustyns I., et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. DavosSwitzerland 24 February – 1 March, 2002, Poster presented at the 11th Biennial Winter Workshop on Schizophrenia,
   Google Scholar
• Eerdekens M., Rasmussen M., Vermeulen A., et al. Kinetics and safety of a novel risperidone depot formulation. BrusselsBelgium 9 – 13July, 2000, 22nd Congress of the College of International Neuropsychopharmacology.
   Google Scholar
• Faigle J. W., Feldman K. F. Carbamazepine. Chemistry and biotransformation. Antiepileptic drugs 4th edn, R. H. Levy, R. H. Mattson, B. S. Meldrum. Raven Press, New York 1995; 499–513
   Google Scholar
• Fleischhacker W. W., Eerdekens M., Xie Y., et al. Long-term safety and efficacy of Risperdal Consta, a long-acting injection formulation of risperidone. HawaiiUSA 9 – 13 December, 2001, Poster presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology,
   Google Scholar
• Frye M. A., Ketter T. A., Altshuler L. L., Denicoff K., Dunn R. T., Kimbrell T. A., Cora-Locatelli G., Post R. M. Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics. Journal of Affective Disorders 1998; 48: 91–104
   PubMed Web of Science ®Google Scholar
• Gaertner I., Altendorf K., Batra A., Gaertner I. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7263 treatment courses. Journal of Clinical Psychopharmacology 2001; 21: 215–222
   PubMed Web of Science ®Google Scholar
• Gefuert O., Nyberg S., Persson P., et al. Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia. ArizonaUSA 28 – 31 May, 2001, 41st Annual Meeting of the New Chemical and Drug Evaluation Unit, Phoenix,
   Google Scholar
• Ghaemi S. N., Pardo T. B., Hsu D. J. Strategies for preventing the recurrence of bipolar disorder. Journal of Clinical Psychiatry 2004; 65(Suppl. 10)16–23
   PubMedGoogle Scholar
• Gitlin M. J., Swendsen J., Heller T. L., Hammen C. Relapse and impairment in bipolar disorder. American Journal of Psychiatry 1995; 152: 1635–1640
   PubMed Web of Science ®Google Scholar
• Greil W., Kleindienst N., Erazo N., Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology 1998; 18: 455–460
   PubMed Web of Science ®Google Scholar
• Hagström P., Hansson B. -M. Practical handling aspects of long-lasting risperidone microspheres (Risperdal Consta): An attitude survey. Nordic Journal of Psychiatry 2002; 56: 18
   Google Scholar
• Hirschfeld R. M., Keck P. E., Jr, Kramer M., Karcher K., Canuso C., Eerdekens M., Grossman F. Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trial. American Journal of Psychiatry 2004; 161: 1057–1065
   PubMed Web of Science ®Google Scholar
• Janssen-Cilag Ltd. Risperdal Consta, Risperidone long-acting injection, Summary of Product Characteristics
   Google Scholar
• Kane J., Eerdekens, Keith S., et al. Efficacy and safety of Risperdal Consta, a long-acting injection risperidone formulation. DavosSwitzerland 24 February – 1 March, 2002, Poster presented at the 11th Biennial Winter Workshop on Schizophrenia,
   Google Scholar
• Keck P. E. Defining and improving response to treatment in patients with bipolar disorder. Journal of Clinical Psychiatry 2004; 65(Suppl. 1)25–29
   PubMedGoogle Scholar
• McIntyre R. S., Mancini D. A., Lin P., Jordan J. Treating bipolar disorder. Evidence-based guidelines for family medicine. Canadian Family Physician 2004; 50: 388–394
   PubMed Web of Science ®Google Scholar
• Montgomery S., Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Müller-Oerlinghausen B., Berghöfer A., Bauer M. Bipolar disorder. Lancet 2002; 359: 241–247
   PubMed Web of Science ®Google Scholar
• Reilly J. G., Ayis S. A., Ferrier I. N., Jones S. J., Thomas S. H. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–1052
   PubMed Web of Science ®Google Scholar
• Sachs G. S., Grossman F., Ghaemi S. N., Okamoto A., Bowden C. L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. American Journal of Psychiatry 2002; 159: 1146–1154
   PubMed Web of Science ®Google Scholar
• Segal J., Berk M., Brook S. Risperidone compared with lithium and haloperidol in mania: double-blind randomized controlled trial. Clinical Neuropharmacology 1998; 21: 176–180
   PubMed Web of Science ®Google Scholar
• Taylor D. Depot antipsychotics revisited. Psychiatric Bulletin 1999; 23: 551–553
   Google Scholar
• Tondo L., Jamison K. R., Baldessarini R. J. Effect of lithium maintenance on suicidal behaviour in major mood disorders. Annals of the New York Academy of Science 1997; 836: 339–351
   PubMed Web of Science ®Google Scholar
• Vieta E. Olanzapine in bipolar disorder. Expert Opinion in Pharmacotherapy 2004; 5: 1613–1619
   PubMed Web of Science ®Google Scholar
• Vieta E., Brugue E., Goikolea J. M., Sanchez-Moreno J., Reinares M., Comes M., et al. Acute and continuation risperidone monotherapy in mania. Human Psychopharmacology 2004; 19: 41–45
   PubMed Web of Science ®Google Scholar
• Weizman R., Weizman A. Use of typical antipsychotics in mood disorders. Current Opinion and Investigative Drugs 2001; 2: 940–945
   PubMedGoogle Scholar
• Wyatt R. J., Henter I. An economic evaluation of manic depressive illness: 1991. Society of Psychiatry and Psychiatric Epidemiology 1995; 30: 213–219
   PubMed Web of Science ®Google Scholar
• Yatham L. N. Newer anticonvulsants in the treatment of bipolar disorder. Journal of Clinical Psychiatry 2004; 65(Suppl. 10)28–35
   PubMed Web of Science ®Google Scholar
• Yatham L. N., Grossman F., Augustyns I., Vieta E., Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. British Journal of Psychiatry 2003; 182: 141–147
   PubMed Web of Science ®Google Scholar